Global Acne Drugs Market

The transdermal skin patches market consists of sales of transdermal skin patches products and related services used to provide medicine to the human body through patches. Transdermal skin patches involve the use of adhesive patches made up of polymers that contains drugs. The drugs from these patches are absorbed into the body and eventually into the blood stream eliminating the drug delivery through pill, or injections. The transdermal skin patches covered in this report is segmented by product into matrix, drug in adhesive, reservoir, vapor. The transdermal skin patches market is also segmented by type into fentanyl transdermal patch, nicotine transdermal patch, buprenorphine transdermal patch, clonidine transdermal patch, oxybutynin transdermal patch, others and by application into pain relief, nicotine cessation, hormone replacement therapy, neurological disorders, cardiovascular disorders, others. The global transdermal skin patches market is expected to grow from $6.15 billion in 2020 to $6.54 billion in 2021 at a compound annual growth rate (CAGR) of 6.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The transdermal skin patches market is expected to reach $7.67 billion in 2025 at a CAGR of 4%. The advances in the modern technologies contribute to the growth of transdermal skin patches market. Advances in modern technologies increase the number of drugs being delivered transdermally including small molecule hydrophobic drugs, hydrophilic drugs, and macromolecules. The new technological advances add to the increased efficiency and increased use of transdermal drug delivery systems (TDDS) thus, increasing the popularity and demand for TDDS. For instance, in 2019, few technological advances in the TDDS included transdermal patch formulation improvements, introduction of pressure-sensitive adhesives and permeation enhancers, which lead to increased product diffusion and increased drug retention ability in larger quantities. The advances in technologies are expected to increase the demand for transdermal patches owing to its benefits thereby driving the growth of the market. Stringent regulatory approval by the government regulatory bodies is a key factor hindering the growth of the transdermal skin patches market. The regulatory authority enforces the laws regulating biologics, medications, and medical devices, which can have potential side effects for customers. For instance, Food and Drug Administration (FDA) mandates the TDDS to undergo series of tests including biomechanical testing, animal testing, and clinical trials before approving the TDDS for use in the market. The whole process consumes time and may result in delay for the launch of TDDS into the market losing the first-mover advantage thus restraining the growth of the transdermal skin patch market. Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand their footprint for the growth of the transdermal skin patches market. The strategic merger and acquisition and collaboration followed by the players in the transdermal skin patches market allows the companies to take technological advantage by acquiring the technology which allows them to get ahead in the competition. For instance, in 2019, Canoa Inc., a Delaware based healthcare and pharmaceuticals company, acquired ProSolus® Inc. To enhance its position and development of new products in transdermal space. ProSolus headquartered in the USA is a pharmaceutical company that provides transdermal solutions. Similarly, in 2019, Mylan, a pharmaceutical company providing transdermal skin patches, with Upjohn, a subsidiary of Pfizer announced the formation of a new company named Viatris. The aim of the new collaboration is to provide more innovative medicines to the patients globally. Pfizer is a multinational pharmaceutical company. Thus, companies operating in the transdermal skin patch market are following the strategic collaborations and acquisitions to have a competitive edge. In 2018, Nutriband Inc., a USA based pharmaceutical and health care-based provider that focuses on transdermal and Topical technologies acquired 4P Therapeutics Inc for an undisclosed amount. Through the acquisition, Nutriband aimed to expand its product portfolio to include the transdermal technologies, prescription drugs and clinical development. 4P Therapeutics Inc is a U.S.A based biotechnology health-care research and development company that focuses on novel methods for drugs delivery. Major players in the transdermal skin patches market are Mylan Pharmaceuticals Inc, Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan, Actavis, Mundipharma, Henan Lingrui Pharmaceutical and Changzhou Siyao. The regions covered in the transdermal skin patches market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the transdermal skin patches market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global transdermal skin patches market is segmented - 1) By Product: Matrix, Drug In Adhesive, Reservoir, Vapor 2) By Type: Fentanyl Transdermal Patch, Nicotine Transdermal Patch, Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Oxybutynin Transdermal Patch, Others 3) By Application: Pain Relief, Nicotine Cessation, Hormone Replacement Therapy, Neurological Disorders, Cardiovascular Disorders, Others

The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them. Dermatology medical lasers are used in the treatment of medical conditions related to the skin and for cosmetic procedures such as scar removal, skin rejuvenation, skin lightening, hair removal and tattoo removal. The global dermatology medical lasers market is expected to grow from $2.546 billion in 2020 to $3.087 billion in 2021 at a compound annual growth rate (CAGR) of 21.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.509 billion in 2025 at a CAGR of 16%. The growing demand for cosmetic procedures is expected to drive the dermatology medical lasers market. There has been an increase in the number of people opting for cosmetic procedures to enhance the appearance levels and treatment of defects on the skin. As per the report of the American Society of Plastic Surgeons (ASPS), Americans spent $16.5 million on cosmetic procedures in 2018 and nearly 17.7 million cosmetic procedures were performed in 2018 up by 2% from 2017. Dermatology lasers are used in cosmetic procedures such as removal of fine lines, wrinkles, skin tightening, pigmented lesions, precancerous lesions, vascular lesions, tattoos, hair removal, acne scars, and others. Hence, the growing demand for cosmetic procedures among users aids in the growth of the dermatology medical lasers market. Alternatives for laser skin treatment are expected to hinder the dermatology medical lasers market. The growing popularity of alternative methods of skin treatment such as the use of drugs, chemical treatment, microneedle and Botox surgery is expected to hinder the growth of the market. For instance, as per the survey by eMediHealth of 64 dermatologists from October to November 2019, drug therapy such as Isotretinoin and retinoids have a higher success rate for acne treatment with 75% dermatologist preferring it over laser therapy. Thus, the demand for alternatives is expected to restrain the market growth. Companies are increasingly investing in Picosecond Lasers for skin treatments other than tattoo removal as they have found their use in the treatment of acne, skin lightening and skin tightening. For instance, in July 2018, Picocare 450, manufactured by Wontech, a South Korea company, received FDA approval to be used in dermatology procedures. In February 2019, LaserOptek received FDA clearance for its PicoLO picosecond laser device used for the treatment of scars and skin rejuvenation. Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market. In March 2020, SemiNex Corporation, a U.S-based high-diode manufacturer, announced its collaboration with Dermal Photonics Corporation, a manufacturer of Nira skincare - a professional home laser technology. Through this collaboration, SemiNex Corporation plans to enhance home-based lasers for dermatology procedures. Dermal Photonics is a US-based medical device company. The major players covered in the global dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Laser, SemiNex Corporation, Alma Lasers Ltd, Cutera, Lumenis, and Bausch Health Companies Inc. The countries covered in the global dermatology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global dermatology medical lasers market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global dermatology medical lasers market is segmented - 1) By Device: Surgical Lasers, Vascular Lasers 2) By End-Users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres 3) By Application: Cancer, Hair Removal, Tattoo Removal, Resurfacing, Others

The skin cancer drugs market consists of sales of skin cancer drugs. Skin cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma. Examples of skin cancer drug include 5-FU, Aldara and Efudex. The global skin cancer drugs market is expected to grow from $1.44 billion in 2020 to $1.61 billion in 2021 at a compound annual growth rate (CAGR) of 11.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.72 billion in 2025 at a CAGR of 14%. Significant rise in prevalence of skin cancer is driving the demand for the drugs for Skin Cancer. To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured. According to the American Academy Of Dermatology, 192,310 new cases of Melanoma type skin cancer were expected in 2019. Additionally, non-invasive type skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in US in 2019. According to the American Academy Of Dermatology, each year roughly around 3 million Americans get diagnosed by skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market. Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only. The chemical drugs attack any fast dividing cells while targeted therapies only attack the skin cancer causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward. Companies in the skin cancer market are increasingly looking for strategic alliances with other companies in the market. Strategic alliances help companies to enhance their R&D capability, expedite the development process of new drugs and reinforce competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm in 2018, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug pertaining to skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. EMA also educates the patients regarding the risks associated in taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, benefits of the drug and all other relevant information pertaining to such drugs. In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of drug in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States. Major players in the market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd. The countries covered in the global skin cancer drugs market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global skin cancer drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma 2) By End Users: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs

The shaving preparations market consists of sales of shaving preparations and related services that include shaving cream or foam, which is a frothy cosmetic cream applied to remove body hair mainly facial hair. Shaving creams comprises emulsion of oils, soaps or surfactants, and water that helps in lubricating the cutting process, swelling keratin and desensitizing skin. The global shaving preparations market is expected to grow from $0.44 billion in 2020 to $0.51 billion in 2021 at a compound annual growth rate (CAGR) of 15.9%.The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.69 billion in 2025 at a CAGR of 8%. The shaving preparations market covered in this report is segmented by type into shave foams, shaving creams, shaving lotions, shaving waxes, shave gels. The increasing adoption of self-grooming and personal care products is driving the shaving preparations market. Men and women are well aware of how to get rid of body hair and use of hair removal products extensively through advertisements, social media blogs. In addition, with the introduction of sensitive razors and shaving creams that are more economical and causes less irritation and soften the beard and make the skin smooth & moisturized and help reduce cuts while shaving. For instance, According to the Simmons National Consumer Survey (NHCS), in the USA, in 2019, 2.13 million Americans used shaving cream or gel, 14 or more times in a week. Cosmetic and personal care products suppliers faced uncertain regulatory environment globally. Product safety and consumer safety are the most essential concern for the manufacturing companies along with the U.S. Food and Drug Administration (FDA). FDA strictly regulated U.S. Food, Drug, and Cosmetic Act (FD&C Act) for personal care products companies and manufacturers. According to the FD&C Act, every personal care product and its ingredients should meet the requirements of law with additional consumer safety measures. In addition, all the ingredients be substantiated for safety before going to market. Thus, regulations on ingredients hinder the growth of the shaving preparations market. Increasing demand for wet shaving kits contributing to the growth of the shaving preparations market. Wet shaving process provides cleaner scrape than the dry shaving method which often leads to less irritation, and soften skin & growth of beard. Many companies are also offering a wide range of razors, shaving creams or soap, shaving brush and after shaving lotion at an economical rate which keeps skin pores clean and bacteria free and prevent acne. According to a survey conducted by Prim & Prep, in the USA, aged 18+, 61% of men respondents are concerned about razor burns & bumps and 58% of men respondents shave atleast thrice a week. In May 2019, Edgewell Personal Care, an American consumer goods company, the parent company of Schick and Wilkinson razor brands, acquired the Harry's Inc. for $1.37 billion. The acquisition aimed to create a direct, branded relationship with consumers and strengthen the market position in shaving and grooming products. Harry’s Inc., an USA based company, specialized in manufacturing of razors, shaving creams, and body wash products. The major players covered in the global shaving preparations market are The Procter and Gamble Company, L'Oréal Group, Gillette, Johnson & Johnson, Colgate-Palmolive, Energizer Holdings, Godrej, Beiersdorf AG, Unilever PLC, Perio, Super-Max, Taylor of Old Bond Street, AHAVA, VI-John Group, Avon Products, Inc., Shiseido Company Limited, Estee Lauder Companies, Inc., Biotherm, Pierre Fabre Dermo-Cosmetique USA, Mary Kay Inc., Roger & Gallet, Bulldog Skincare, Lush North America, Acqua di Parma, Bold for Men, Castle Forbes, Beiersdorf. The countries covered in the global shaving preparations market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global shaving preparations market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global shaving preparations market is segmented - 1) By Product Type: Shave Foams, Shaving Creams, Shaving Lotions, Shaving Waxes, Shave Gels 2) By End-Use: Salons, Personal Use 3) By Sales Channel: Beauty and Drug Stores, Branded and Specialty Outlets, Online Retailers, Convenience Stores, Other Retailing Formats

The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them. Dermatology medical lasers are used in the treatment of medical conditions related to the skin and for cosmetic procedures such as scar removal, skin rejuvenation, skin lightening, hair removal and tattoo removal. The global dermatology medical lasers market is expected to grow from $2.546 billion in 2020 to $3.087 billion in 2021 at a compound annual growth rate (CAGR) of 21.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.509 billion in 2025 at a CAGR of 16%. The growing demand for cosmetic procedures is expected to drive the dermatology medical lasers market. There has been an increase in the number of people opting for cosmetic procedures to enhance the appearance levels and treatment of defects on the skin. As per the report of the American Society of Plastic Surgeons (ASPS), Americans spent $16.5 million on cosmetic procedures in 2018 and nearly 17.7 million cosmetic procedures were performed in 2018 up by 2% from 2017. Dermatology lasers are used in cosmetic procedures such as removal of fine lines, wrinkles, skin tightening, pigmented lesions, precancerous lesions, vascular lesions, tattoos, hair removal, acne scars, and others. Hence, the growing demand for cosmetic procedures among users aids in the growth of the dermatology medical lasers market. Alternatives for laser skin treatment are expected to hinder the dermatology medical lasers market. The growing popularity of alternative methods of skin treatment such as the use of drugs, chemical treatment, microneedle and Botox surgery is expected to hinder the growth of the market. For instance, as per the survey by eMediHealth of 64 dermatologists from October to November 2019, drug therapy such as Isotretinoin and retinoids have a higher success rate for acne treatment with 75% dermatologist preferring it over laser therapy. Thus, the demand for alternatives is expected to restrain the market growth. Companies are increasingly investing in Picosecond Lasers for skin treatments other than tattoo removal as they have found their use in the treatment of acne, skin lightening and skin tightening. For instance, in July 2018, Picocare 450, manufactured by Wontech, a South Korea company, received FDA approval to be used in dermatology procedures. In February 2019, LaserOptek received FDA clearance for its PicoLO picosecond laser device used for the treatment of scars and skin rejuvenation. Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market. In March 2020, SemiNex Corporation, a U.S-based high-diode manufacturer, announced its collaboration with Dermal Photonics Corporation, a manufacturer of Nira skincare - a professional home laser technology. Through this collaboration, SemiNex Corporation plans to enhance home-based lasers for dermatology procedures. Dermal Photonics is a US-based medical device company. The major players covered in the global dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Laser, SemiNex Corporation, Alma Lasers Ltd, Cutera, Lumenis, and Bausch Health Companies Inc. The countries covered in the global dermatology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global dermatology medical lasers market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global dermatology medical lasers market is segmented - 1) By Device: Surgical Lasers, Vascular Lasers 2) By End-Users: Hospitals, Skin Care Clinics, Cosmetic Surgical Centres 3) By Application: Cancer, Hair Removal, Tattoo Removal, Resurfacing, Others

The sodium cocoyl isethionate market consists of sales of sodium cocoyl isethionate by entities (organizations, sole traders and partnerships) that manufacture sodium cocoyl isethionate. Sodium cocoyl isethionate is a component that is extracted from coconut oil. Sodium Cocoyl Isethionate is used mainly in the creation of bath soaps and cleaning ingredients for beauty and personal care products. The sodium cocoyl isethionate market covered in the report is segmented by type into powder, needles and flakes, granules; by product type into cleansing sodium cocoyl isethionate, hair conditioning sodium cocoyl isethionate, surfactant sodium cocoyl isethionate, others; by application into skincare, hair care, baby care, oral care, others. The global sodium cocoyl isethionate market is expected to grow from $145.60 million in 2020 to $155.36 million in 2021 at a compound annual growth rate (CAGR) of 6.7%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $199.91 million in 2025 at a CAGR of 6.5%. The growing demand for skincare products is expected to drive the growth of the sodium cocoyl isethionate market in the coming years. Skincare products, such as face masks and body scrubs, play an important role in self-care routines. Sodium cocoyl isethionate is a solvent that allows water, oil, and dirt to be combined to make things clean. Sodium cocoyl isethionate can be used in hundreds of skincare products such as facial cleansers, bar soap, acne products, styling products and other products. According to Trefis, a financial research and analysis company, the global skincare industry was worth almost $135 billion in 2018, rising almost 60% in the last 10 years, and Trefis estimates it to hit $180 billion, a rise of over 30% over the next five years. Therefore, the growing demand for skincare products drives the growth of the sodium cocoyl isethionate market. The high cost of sodium cocoyl isethionate is expected to hamper the growth of the sodium cocoyl isethionate market in the coming years. Sodium Cocoyl Isethionate is a component that is extracted from coconut oil. Sodium Cocoyl Isethionate is used mainly in the creation of bath soaps and cleaning ingredients for beauty and personal care products. The cost of sodium cocoyl isethionate is high as it is made from natural coconut oil and is completely biodegradable. For instance, Alexmo Cosmetics, a Germany-based cosmetics company charges $33.11 per 1 kg for sodium cocoyl isethionate powder. Therefore, the high cost of sodium cocoyl isethionate restraints the growth of the sodium cocoyl isethionate market. The launch of innovative products consisting of sodium cocoyl isethionate is a major trend gaining popularity in the market. Major companies operating in the sodium cocoyl isethionate sector are focusing on developing innovative solutions for sodium cocoyl isethionate. For instance, in March 2020, Groupe GM, a Paris-based hospitality company, introduced a solid amenity bath line called Damana Earth & Sun made from a mixture of mild surfactants, such as sodium cocoyl isethionate extracted from coconut oil, emulsifiers and emollients. These dermatological products are genuinely soap-free, allowing them suitable for sensitive and atopic skin. In March 2020, Akzo Nobel N.V., a Netherland-based company that creates paints and performance coatings for both industry and consumers, acquired the remaining 25% stake in previously acquired Akzo Nobel Boya Sanayi ve Ticaret A.S for an undisclosed amount. This acquisition will help to consolidate AkzoNobel’s strong position in powder coatings in Turkey. Akzo Nobel Boya Sanayi ve Ticaret A.S, a Turkey-based company that manufactures and distributes powder coating. The major players covered in the global sodium cocoyl isethionate market are Akzo Nobel N.V, Innospec Inc., Galaxy Surfactants Ltd., Taiwan NJC Corporation, BASF SE, Clariant International Ltd, KIYU New Material Co. Ltd, Henan Surface Chemical Industry Co. Ltd., Huanggang Yongan Pharmaceutical Co. Ltd, Earth Science Beauty, L'Oreal. The countries covered in the global sodium cocoyl isethionate market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. North America was the largest region in the sodium cocoyl isethionate market in 2020. The regions covered in the global sodium cocoyl isethionate market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global sodium cocoyl isethionate market is segmented - 1) By Type: Powder, Needles And Flakes, Granules 2) By Product Type: Cleansing Sodium Cocoyl Isethionate, Hair Conditioning Sodium Cocoyl Isethionate, Surfactant Sodium Cocoyl Isethionate, Others 3) By Application: Skin Care, Hair Care, Baby Care, Oral Care, Others

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne, microbial infections and other skin disorders. The dermatology market is segmented into acne; dermatitis; psoriasis; and other drugs for dermatology diseases. The global dermatology drugs market is expected to grow from $37.57 billion in 2020 to $40.49 billion in 2021 at a compound annual growth rate (CAGR) of 7.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $62.83 billion in 2025 at a CAGR of 12%. Asia Pacific was the largest region in the global dermatology drugs market, accounting for 36% of the market in 2020. North America was the second largest region, accounting for 27% of the global dermatology drugs market. Africa was the smallest region in the global dermatology drugs market. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP grew from $11 trillion in 2015 to $13.6 trillion in 2018. Additionally, according to the World Economic Outlook Reports by the IMF, emerging markets and developing economies together registered a growth of 4.0% in 2015 and this increased to 4.5% in 2018. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. The major players covered in the global dermatology drugs market are Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc. The countries covered in the global dermatology drugs market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global dermatology drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global dermatology drugs market is segmented - 1) By Type: Acne, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The pharmaceutical drug market consists of sales of goods and related services by entities (organizations, sole traders and partnerships) that produce and sell pharmaceutical drugs used to treat various diseases. This industry includes establishments that produce drugs such as cardiovascular drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs and other drugs used to treat cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others. The pharmaceutical drug market is segmented into cardiovascular drugs; dermatology drugs; gastrointestinal drugs; genito-urinary drugs; hematology drugs; anti-infective drugs; metabolic disorders drugs; musculoskeletal disorders drugs; central nervous system drugs; oncology drugs; ophthalmology drugs; and respiratory diseases drugs. The global pharmaceutical drugs market is expected to grow from $975.04 billion in 2020 to $981.73 billion in 2021 at a compound annual growth rate (CAGR) of 0.7%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1280.42 billion in 2025 at a CAGR of 7%. North America was the largest region in the global pharmaceutical drugs market, accounting for 44% of the market in 2020. Asia Pacific was the second largest region, accounting for 27% of the global pharmaceutical drugs market. Africa was the smallest region in the global pharmaceutical drugs market. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drugs market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period; this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research and development of new products. For instance, the US interest rates are expected to rise up to 3.5% by 2021. These factors are expected to have a negative impact on the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020 FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2%(Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed and grass. The major players covered in the global pharmaceutical drugs market are Novartis AG, Sanofi S.A., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson. The countries covered in the global pharmaceutical drugs market are.Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global pharmaceutical drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations